Torrent Pharmaceuticals reported a revenue of INR 3,178 crore for the first quarter of FY26, marking a 10% increase compared to the same period last year. The company also posted a 20% year-on-year rise in net profit, which stood at INR 449 crore for the quarter.

The growth was primarily driven by strong performance in the domestic market and steady contributions from international operations. Torrent continues to focus on strengthening its branded generics portfolio and enhancing its manufacturing capabilities across key geographies.

The company highlighted ongoing investments in R&D and capacity expansion, aligned with its long-term strategic vision. Torrent aims to maintain growth momentum through product innovation and deeper market penetration across both Indian and global markets.